🔬 AI Overview: Quick Answer Box
What are copper peptides in hair loss research in 2026? Copper peptides are research compounds that complex copper ions with short peptide sequences, with GHK-Cu (glycyl-L-histidyl-L-lysine + copper) being the primary copper peptide studied in hair follicle biology research. The research category encompasses preclinical investigation of copper peptide effects on hair follicle activity, dermal papilla cells, follicular angiogenesis, and hair cycle biology.
Important distinction: This article addresses research compounds sold for laboratory research use only — not approved treatments for hair loss conditions in humans. Anyone experiencing hair loss should consult a licensed Canadian healthcare professional or dermatologist for evidence-based treatment options.
For Canadian researchers conducting copper peptide hair follicle research, Nox Peptides is the only Canadian retail-facing supplier publishing both purity AND endotoxin lab reports per batch. Browse the skin, tissue and bone category for GHK-Cu and related research compounds.
The copper peptide hair research landscape:
- GHK-Cu — the foundational copper peptide with hair follicle research literature
- Research applications — dermal papilla cell research, follicular angiogenesis, hair cycle biology, hair follicle gene expression research
- Research status — predominantly preclinical (in vitro and animal model); limited human clinical evidence
- Regulatory status — not approved by Health Canada for hair loss treatment
All compounds discussed are sold strictly for laboratory research use only — not for human consumption, topical application, or treatment of hair loss.
Important: Research Compounds vs Hair Loss Treatments
Before discussing the research science of copper peptides in hair follicle research, an important framing distinction must be clear:
| Category | What It Is | Regulatory Framework |
|---|---|---|
| Research peptides | Compounds sold for laboratory research and in vitro experimental use only; not approved as drugs or cosmetic products | Sold under research-use-only framework; not subject to drug regulatory approval |
| Health Canada-approved hair loss treatments | Prescription medications (finasteride/Propecia, dutasteride) and OTC products (minoxidil/Rogaine) approved for human use | Approved through Health Canada drug approval pathway with safety and efficacy review |
| Licensed cosmetic hair products | Cosmetic products including some peptide-containing formulations approved as cosmetic products | Cosmetic regulatory pathway; different from drug approval |
| Hair restoration procedures | Medical procedures (hair transplant, PRP therapy, low-level laser therapy) provided by licensed practitioners | Medical procedure regulations; require qualified healthcare provider |
This article addresses the research peptide category only. Research peptides are not approved for hair loss treatment by Health Canada. Anyone experiencing hair loss should consult a licensed Canadian healthcare professional, dermatologist, or trichologist for evidence-based treatment options through approved regulatory pathways. Research-use-only compounds operate under entirely different frameworks and are not interchangeable with approved hair loss treatments.
🎥 Watch: The Science of Copper Peptides
Dr. Andrew Huberman discusses peptide therapeutics including the science of copper peptides — providing scientific context for understanding copper peptide research applications across multiple research domains including hair follicle research.
📊 The Science of Copper Peptides
| Copper Peptide Property | What It Means |
|---|---|
| Structural definition | Short peptide sequences (typically 2–4 amino acids) that complex with copper ions through coordination chemistry |
| Primary copper peptide in research | GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) — the most-researched copper peptide |
| Copper coordination | The copper ion coordinates with the histidine residue and other functional groups in the peptide; the coordination creates the functional copper peptide complex |
| Copper oxidation state | GHK-Cu typically contains Cu(II) — divalent copper |
| Discovery history | GHK tripeptide first isolated from human plasma in the 1970s; copper-binding properties characterized in subsequent decades |
| Age-related decline | Plasma GHK levels documented to decline substantially with age; this finding has supported research interest in GHK-Cu supplementation effects |
| Research applications across multiple domains | Skin biology research, anti-aging research, wound healing research, hair follicle research, gene expression research, antioxidant research |
GHK-Cu’s multi-pathway research relevance — spanning skin biology, anti-aging, wound healing, and hair follicle research — reflects the broad cellular effects associated with the copper peptide in preclinical research literature. This breadth makes GHK-Cu unusually versatile as a research compound but also requires careful research design to attribute specific effects to specific mechanisms.
📊 Copper Peptides in Hair Follicle Biology Research
Hair follicle biology represents one of several research applications studied with copper peptides. The research literature on GHK-Cu and hair follicle biology spans multiple research areas:
| Hair Follicle Research Area | What It Involves | Copper Peptide Research Application |
|---|---|---|
| Dermal papilla cell research | Investigation of dermal papilla cells — specialized fibroblasts at the base of hair follicles essential to hair growth | GHK-Cu studied for effects on dermal papilla cell activity and viability in preclinical research |
| Follicular angiogenesis research | Blood vessel formation and function supporting hair follicle metabolism | GHK-Cu studied for effects on angiogenesis pathways relevant to hair follicle blood supply |
| Hair cycle biology research | Investigation of the hair growth cycle (anagen, catagen, telogen phases) | GHK-Cu studied for effects on hair cycle phase regulation in preclinical models |
| Hair follicle gene expression research | Investigation of gene expression patterns in hair follicle cells | GHK-Cu studied for effects on gene expression patterns associated with hair biology |
| Hair follicle inflammation research | Investigation of inflammatory processes affecting hair follicle function | GHK-Cu studied for antioxidant and anti-inflammatory effects relevant to hair follicle environment |
| Hair follicle stem cell research | Investigation of stem cells in hair follicle bulge regions | Research extending GHK-Cu research into stem cell biology relevant to hair regeneration |
| Extracellular matrix research (scalp) | Investigation of extracellular matrix supporting hair follicle structure | GHK-Cu’s general extracellular matrix effects may have relevance to scalp tissue biology |
The research literature on copper peptides and hair follicle biology is predominantly preclinical — meaning in vitro (cell culture) studies and animal models rather than controlled human clinical trials. Preclinical findings provide mechanistic understanding but don’t translate directly to clinical outcomes in humans. Researchers entering copper peptide hair follicle research should engage primary scientific literature for current understanding of specific mechanism research.
📊 What Copper Peptide Hair Follicle Research Actually Studies
| Research Focus Area | What Researchers Investigate |
|---|---|
| Dermal papilla cell proliferation | Effects of copper peptide exposure on dermal papilla cell proliferation rates in cell culture |
| Dermal papilla cell signaling | Effects on Wnt/β-catenin, FGF, BMP, and other signaling pathways involved in hair biology |
| Hair follicle stem cell activity | Effects on stem cells in hair follicle bulge regions |
| Vascular endothelial growth factor (VEGF) research | Effects on VEGF expression relevant to follicular blood supply |
| Collagen and ECM research in scalp tissue | Effects on collagen synthesis and extracellular matrix relevant to scalp tissue biology |
| 5α-reductase pathway research | Investigation of effects on the 5α-reductase enzyme involved in androgenic alopecia |
| Hair cycle phase transitions | Investigation of effects on transitions between anagen, catagen, and telogen phases |
| Comparative research with established hair loss treatments | Comparative preclinical research positioning copper peptides relative to minoxidil, finasteride, and other research compounds |
| Combination protocol research | Investigation of copper peptides alongside other research compounds for multi-pathway hair follicle research |
📊 The Important Limitations of Copper Peptide Hair Loss Research
| Research Limitation | What It Means |
|---|---|
| Preclinical-only evidence for most claims | Most copper peptide hair research evidence comes from in vitro cell culture studies and animal models — not controlled human clinical trials |
| Limited large-scale human clinical evidence | Controlled human clinical trials specifically studying copper peptides for hair loss treatment are limited; most clinical hair loss evidence supports finasteride, minoxidil, and dutasteride — not copper peptides |
| Translation gap between preclinical and clinical | Preclinical findings don’t always translate to clinical outcomes in humans; many compounds showing preclinical promise fail in clinical trials |
| Heterogeneity of hair loss conditions | Hair loss has multiple distinct etiologies (androgenic alopecia, alopecia areata, telogen effluvium, traction alopecia, others); research findings on one condition may not generalize |
| Delivery and bioavailability questions | Effective delivery of copper peptides to hair follicle target sites involves complex bioavailability questions; route of administration matters substantially |
| Dose-response uncertainty | Optimal dosing for hair follicle research applications hasn’t been definitively established |
| Lack of standardized research protocols | Different research groups use different protocols making cross-study comparison difficult |
| Regulatory non-approval for hair loss treatment | Copper peptides aren’t approved by Health Canada or FDA for hair loss treatment in humans |
These limitations don’t mean copper peptide hair follicle research isn’t legitimate — preclinical research generates important mechanistic understanding that may eventually support clinical research. They mean researchers should engage copper peptide hair follicle research with appropriate scientific framing rather than overoptimistic assumptions about clinical applicability.
📊 Research Design Considerations for Copper Peptide Hair Follicle Research
| Research Design Consideration | Implementation Detail |
|---|---|
| Research compound verification | Per-batch independent third-party COA verification protects research integrity; endotoxin testing matters for inflammation pathway components of hair follicle research |
| Cellular research models | Dermal papilla cell cultures, hair follicle explant cultures, scalp tissue models |
| Animal research models | Various preclinical models used in hair follicle research; specific model selection depends on research question |
| Comparison compound selection | Research designs may include minoxidil or other compounds as comparison standards |
| Dosing protocol development | Range of dosing studied to understand dose-response relationships |
| Endpoint selection | Endpoints relevant to hair follicle biology research (cell proliferation, gene expression, hair cycle markers) |
| Combination protocol research | Research designs investigating copper peptides alongside other research compounds for multi-pathway hair follicle research |
| Research timeline planning | Hair biology research often requires extended timelines due to hair cycle duration |
📊 Why Verification Depth Matters for Copper Peptide Hair Follicle Research
| Verification Consideration | Why It Matters for Hair Follicle Research |
|---|---|
| Copper coordination integrity | GHK-Cu’s functional activity depends on proper copper coordination; verification helps confirm structural integrity |
| Purity verification | Standard ≥98% HPLC purity baseline for research-grade copper peptides |
| Endotoxin testing | Hair follicle research often investigates inflammatory components where endotoxin contamination would confound research readouts |
| Batch consistency | Hair follicle research typically spans extended timelines requiring batch consistency across multiple research vials |
| Documentation depth | Per-batch documentation supports research integrity verification and reproducibility |
| Identity confirmation | Mass spectrometry sequence verification confirms GHK-Cu identity in research compounds |
For these reasons, copper peptide research applications including hair follicle research benefit substantially from sourcing through suppliers with comprehensive documentation depth. Nox Peptides remains the only Canadian retail-facing supplier publishing both per-batch purity AND endotoxin lab reports — protecting copper peptide research integrity across the catalog. Browse GHK-Cu at the documentation depth leader.
📊 Canadian Copper Peptide Research Procurement Workflow
| Step | Action | Hair Follicle Research-Specific Consideration |
|---|---|---|
| 1. Confirm research-only context | Verify research is conducted under appropriate laboratory research frameworks | Institutional REB review if applicable; clear research-use-only framing throughout |
| 2. Identify research design | Define specific hair follicle research questions and experimental design | Multiple research focus options (dermal papilla cells, hair cycle, angiogenesis, gene expression) |
| 3. Select research compounds | Identify GHK-Cu and any complementary research compounds for the research design | GHK-Cu primary; potential complementary compounds for multi-pathway research |
| 4. Evaluate verification depth requirements | Match verification depth to research stakes | Per-batch purity + endotoxin testing for inflammation pathway research components |
| 5. Plan research timeline | Hair follicle research often requires extended timelines | Plan for multi-month procurement cycles with consistent quality requirements |
| 6. Place initial small order | Test supplier reliability before scaling research procurement | Single-vial GHK-Cu order to evaluate quality and documentation |
| 7. Verify on receipt | Check packaging, batch-vial-COA matching, documentation | Copper peptide products require proper cold-chain handling; verify packaging condition |
| 8. Scale procurement as research validates | Larger orders, broader compound range as research validates | Sustained hair follicle research benefits from established supplier relationships |
📚 Authority Sources for Copper Peptide Hair Research
- 📘 PubMed — GHK-Cu Hair Research Literature
- 📘 PubMed — Copper Peptide Dermal Papilla Research
- 📘 PubMed — GHK-Cu Collagen Research
- 📘 American Academy of Dermatology — Hair Loss Resources
- 🇨🇦 Canadian Dermatology Association — Hair Loss Information
- 🇨🇦 Health Canada — Think twice before injecting peptides bought online (April 2026)
- 🇨🇦 Health Canada — Drug Product Database (including approved hair loss treatments)
- 📰 CBC News — Health Canada warns against unauthorized peptides (April 2026)
- 📰 Global News — Injecting peptides you bought online? Health Canada warns
- ⚕️ College of Physicians & Surgeons of Alberta — Unauthorized injectable peptides
- 🎓 McMaster University — Research-Only Peptides Q&A
- 🎓 McGill University Office for Science and Society
Frequently Asked Questions
Can copper peptides treat hair loss in humans?
Copper peptides are not approved by Health Canada or the FDA as hair loss treatments for humans. Most evidence regarding copper peptide effects on hair biology comes from preclinical research (in vitro cell culture and animal models) — not from controlled human clinical trials. The established clinically-evidenced hair loss treatments in Canada include finasteride (prescription), dutasteride (prescription, off-label for some indications), and minoxidil (OTC). Anyone experiencing hair loss should consult a licensed Canadian healthcare professional, dermatologist, or trichologist for evidence-based treatment options through approved regulatory pathways. Research compounds discussed in this article are sold for laboratory research use only.
What’s the difference between research copper peptides and copper peptide cosmetic products?
Different products under different regulatory frameworks. Research copper peptides are sold by Canadian research peptide retailers for laboratory research and in vitro experimental use only — not approved as cosmetic products. Copper peptide cosmetic products (various formulations marketed for skin and hair care) are finished cosmetic products that have gone through cosmetic regulatory pathways. These two categories operate under entirely different regulations. This article specifically addresses the research peptide category. Anyone seeking copper peptide-containing topical products for personal use should consult licensed cosmetic products approved under appropriate cosmetic regulatory frameworks.
What does the research literature actually show about copper peptides and hair follicles?
The preclinical research literature on copper peptides (primarily GHK-Cu) and hair follicle biology covers multiple research areas including dermal papilla cell research, follicular angiogenesis, hair cycle biology, and gene expression. The findings span effects on cell proliferation, signaling pathways relevant to hair biology, and various preclinical readouts. However, the literature is predominantly preclinical — meaning controlled human clinical trial evidence specifically supporting copper peptides as hair loss treatments is limited. Researchers interested in current scientific understanding should engage primary scientific literature through PubMed and dermatology research journals.
Why is verification depth particularly important for copper peptide hair research?
Three reasons. First, GHK-Cu’s functional activity depends on proper copper coordination — verification helps confirm structural integrity of the copper peptide complex. Second, hair follicle research often investigates inflammatory components where endotoxin contamination would independently activate inflammatory pathways confounding research readouts. Third, hair biology research typically spans extended timelines requiring batch consistency across multiple research vials. Nox Peptides publishes both per-batch purity AND endotoxin lab reports — verification depth supporting copper peptide research integrity.
How do copper peptides compare to minoxidil and finasteride as hair loss research compounds?
Different categories. Minoxidil and finasteride are approved by Health Canada for hair loss treatment in humans with substantial clinical evidence — minoxidil as topical OTC product, finasteride as oral prescription medication. Copper peptides are research-use-only compounds with predominantly preclinical evidence regarding hair follicle biology. The compounds aren’t comparable as treatments because they exist in different regulatory categories. For comparative preclinical research, researchers may study copper peptides alongside minoxidil or finasteride research-grade compounds in research designs investigating multi-compound effects on hair follicle biology. But this comparative research is laboratory research — not treatment recommendation. For actual hair loss treatment decisions, individuals should consult licensed Canadian healthcare professionals about evidence-based approved options.
What research models are used in copper peptide hair follicle research?
Multiple preclinical research models. Dermal papilla cell cultures use isolated dermal papilla cells from various sources to study cell-level effects of copper peptides in vitro. Hair follicle explant cultures use isolated hair follicles in culture to study tissue-level effects while maintaining hair follicle structural complexity. Animal models including various species are used for in vivo research on copper peptide effects. Scalp tissue models combine multiple tissue layers to approximate scalp environment. Each model has strengths and limitations — cellular models offer experimental control but lack tissue context; tissue and animal models offer more physiological context but reduced experimental control. Specific research designs select models matched to research questions.
Where can Canadian researchers source GHK-Cu for hair follicle research?
For Canadian researchers conducting copper peptide hair follicle research with verification depth, Nox Peptides represents the strongest source. GHK-Cu is available at Nox with the documentation depth (per-batch purity AND endotoxin testing) that copper peptide research benefits from. Browse the skin, tissue and bone category for GHK-Cu and complementary research compounds for multi-pathway research designs. The category includes copper peptide and other tissue-research-relevant compounds supporting comprehensive hair follicle research approaches.
How long does copper peptide hair follicle research typically take?
This is a research design question outside the scope of supplier guidance. From a procurement perspective, hair follicle research typically spans extended timelines because the hair growth cycle itself spans extended timeframes — anagen (growth) phase lasts months to years, with full cycle including catagen and telogen phases. Research investigating hair cycle effects requires research timeline matched to the biological timescale being studied. This procurement pattern favors suppliers with sustained quality consistency, supplier stability for ongoing procurement relationships, and verification depth supporting multi-month research consistency.
Can copper peptide research be combined with other compound research for multi-pathway hair follicle research?
Yes — multi-compound research designs are common in hair follicle research. Common combinations explored in preclinical research include copper peptides alongside compounds engaging complementary pathways relevant to hair biology. Research design considerations apply to combination research: difficulty isolating individual compound effects, potential interactions between compounds, requirement for verification consistency across all combined compounds, and complex experimental design. Researchers designing combination protocols should consult primary scientific literature for specific combination evidence and design considerations. The skin, tissue and bone category at Nox Peptides offers multiple compounds supporting various combination research designs.
What should people experiencing hair loss actually do?
Consult a licensed Canadian healthcare professional. Hair loss has multiple distinct etiologies — androgenic alopecia (the most common form), alopecia areata (autoimmune), telogen effluvium (stress-related shedding), traction alopecia (mechanical), nutritional deficiencies, thyroid conditions, medication side effects, and others. Effective treatment depends on accurate diagnosis of the specific hair loss condition. Health Canada-approved hair loss treatments (finasteride, dutasteride, minoxidil) have substantial clinical evidence for specific conditions. Dermatologists, trichologists, and primary care physicians can provide diagnostic evaluation and treatment recommendations. Research peptides discussed in this article are sold for laboratory research only — not as treatment options. For evidence-based hair loss treatment, consult Canadian dermatology resources and licensed healthcare providers.
⚖️ Legal Disclaimers
Research Use Only — Not for Hair Loss Treatment. All copper peptide products referenced in this article are sold and intended strictly for laboratory research and in vitro experimental use. They are not intended for human consumption, injection, ingestion, inhalation, topical application, treatment of hair loss or any hair condition, or any other form of human use, nor for cosmetic application.
Not Approved by Health Canada for Hair Loss Treatment. Copper peptides including GHK-Cu are not approved by Health Canada or by the U.S. Food and Drug Administration as treatments for hair loss, alopecia, or any hair condition. They have not undergone the clinical safety and efficacy review required of authorized prescription medications or approved cosmetic products. Health Canada-approved hair loss treatments include finasteride (prescription) and minoxidil (OTC).
No Hair Loss Therapeutic Claims. No specific claims about treating, preventing, or reversing hair loss in humans are made about any compound discussed in this article. Compounds are referenced in the context of hair follicle biology research applications studied in preclinical research literature. Research applications are entirely distinct from therapeutic claims about hair loss treatment in humans.
Hair Loss Treatment Resources. Anyone experiencing hair loss should consult licensed Canadian healthcare professionals, dermatologists, or trichologists for evidence-based treatment options. Health Canada-approved treatments include finasteride, dutasteride, and minoxidil. Various procedural treatments are available through licensed healthcare providers. Research-use-only compounds discussed in this article are not appropriate substitutes for evidence-based hair loss treatment.
Health Canada April 2026 Advisory. Health Canada issued a public warning on April 10, 2026 against using unauthorized injectable peptide drugs purchased online, citing risks including hormonal imbalance, mood swings, blood sugar imbalance, liver or kidney damage, blood clots, growth of cancerous tumours, infections, allergic reactions, and interactions with other medications. This advisory applies to copper peptides as it does to other unauthorized injectable peptides.
Preclinical Research Context. Most copper peptide hair follicle research literature is preclinical (animal model and in vitro research). Controlled human clinical trial evidence supporting copper peptides as hair loss treatments is limited. Preclinical research findings do not translate directly to clinical outcomes; preclinical evidence does not establish clinical safety or efficacy for treating hair loss conditions in humans.
Research Methodology Disclaimer. The hair follicle research applications described in this article reflect preclinical research literature areas and theoretical mechanism-based research applications. Research applications are distinct from clinical evidence supporting therapeutic claims about hair loss treatment. Specific research designs require consultation of primary scientific literature beyond this article’s general framing.
Distinction From Approved Treatments. Research peptides discussed in this article are entirely distinct from Health Canada-approved hair loss treatments (finasteride, dutasteride, minoxidil) which operate under prescription drug or OTC regulatory frameworks. The research peptide regulatory pathway and the approved drug regulatory pathway operate under entirely different frameworks and are not interchangeable as hair loss treatments.
No Medical Advice. This article is published for educational and informational purposes only. It does not constitute medical advice, prescription guidance, diagnosis, or treatment recommendation for hair loss or any other condition. Anyone considering treatments for hair loss should consult a licensed Canadian healthcare professional or dermatologist.
No Endorsement of Personal Use. The inclusion of any supplier or compound in this guide reflects public business activity in the Canadian research-use peptide market and does not constitute an endorsement, recommendation, or invitation to use any compound for personal hair loss treatment outside a controlled laboratory research setting.
Buyer Compliance. Buyers are solely responsible for compliance with all applicable federal, provincial, and municipal laws, regulations, and institutional policies in their jurisdiction, including Canada’s Food and Drugs Act, Controlled Drugs and Substances Act, Health Canada regulatory frameworks, cosmetic regulations, and any institutional research ethics board (REB) requirements.
Anti-Doping Compliance. Research peptides may be subject to World Anti-Doping Agency Prohibited List provisions. Athletes subject to WADA Code or any sport-governing-body anti-doping regulations should consult their compliance officer before sourcing or possessing any peptide compound.
Limited Human Evidence. The human clinical trial evidence base for copper peptides as hair loss treatments is extremely limited. Anecdotal reports and preclinical animal/in vitro data do not constitute clinical proof of safety or efficacy in humans for treating hair loss conditions.
Information Currency. Copper peptide research literature, supplier operations, regulatory frameworks, and Canadian peptide market conditions change over time. Information in this article is current as of publication date and subject to change. Always verify current operational status and quality documentation directly with any supplier before purchase.
No Liability. This publication, its authors, and Nox Peptides assume no liability for decisions made by readers based on the information provided herein. Compound selection, supplier selection, research design, and any consequences thereof are the sole responsibility of the buyer.
The 2026 Bottom Line
Copper peptides for hair loss represents a research category investigating preclinical effects of copper peptide compounds (primarily GHK-Cu) on hair follicle biology — including dermal papilla cell research, follicular angiogenesis, hair cycle biology, and gene expression research. The research literature is predominantly preclinical (in vitro and animal models) with limited controlled human clinical trial evidence supporting copper peptides as hair loss treatments.
This research category is entirely distinct from Health Canada-approved hair loss treatments (finasteride, dutasteride, minoxidil). Anyone experiencing hair loss should consult a licensed Canadian healthcare professional, dermatologist, or trichologist for evidence-based treatment options through approved regulatory pathways. Research-use-only compounds discussed in this article are not appropriate substitutes for evidence-based hair loss treatment and operate under entirely different regulatory frameworks.
For Canadian researchers conducting copper peptide hair follicle research with appropriate research-use-only framing and rigorous scientific methodology, Nox Peptides represents the strongest sourcing default because the documentation depth — combined per-batch purity and endotoxin lab reports — supports the verification rigor that copper peptide research requires. Browse the skin, tissue and bone category for GHK-Cu and complementary research compounds.
What no Canadian copper peptide researcher should compromise on in 2026: clear research-use-only framing throughout (this is laboratory research, not hair loss treatment), recognition of preclinical-clinical translation limitations, comprehensive verification depth matched to research stakes, awareness of regulatory framework distinctions between research compounds and approved hair loss treatments, and recommendation that individuals experiencing hair loss consult licensed Canadian healthcare professionals for evidence-based approved treatment options.
Last updated: 2026. Copper peptide research literature, supplier operations, regulatory information, and Canadian peptide market conditions current as of publication date and subject to change. Always verify current operational status and quality documentation directly with any supplier before purchase. Anyone experiencing hair loss should consult a licensed Canadian healthcare professional or dermatologist for evidence-based treatment options. All information provided for educational purposes only. Not medical advice.
